SEC Form 4 · accession 0001203311-17-000100
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Dec 11, 2017
Accepted (ET)
Dec 13, 2017 · 8:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 11, 2017 | M | 2,945 | $11.09 | A | 690,091 | D | |
| Common StockF3,F1 | Dec 11, 2017 | S | 2,945 | $56.39 | D | 687,146 | D | |
| Common StockF1 | Dec 11, 2017 | M | 11,787 | $11.09 | A | 698,933 | D | |
| Common StockF4,F1 | Dec 11, 2017 | S | 11,787 | $55.57 | D | 687,146 | D | |
| Common StockF1 | Dec 11, 2017 | M | 2,300 | $11.09 | A | 689,446 | D | |
| Common StockF5,F1 | Dec 11, 2017 | S | 2,300 | $54.67 | D | 687,146 | D | |
| Common StockF1 | Dec 11, 2017 | M | 1,800 | $11.09 | A | 688,946 | D | |
| Common StockF6,F1 | Dec 11, 2017 | S | 1,800 | $53.62 | D | 687,146 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F7 | $11.09 | Dec 11, 2017 | M | 2,945 | D | — | Aug 27, 2018 | Common Stock | 2,945 | 166,542 | D |
| Non-Qualified Stock Option (right to buy)F7 | $11.09 | Dec 11, 2017 | M | 11,787 | D | — | Aug 27, 2018 | Common Stock | 11,787 | 154,755 | D |
| Non-Qualified Stock Option (right to buy)F7 | $11.09 | Dec 11, 2017 | M | 2,300 | D | — | Aug 27, 2018 | Common Stock | 2,300 | 152,455 | D |
| Non-Qualified Stock Option (right to buy)F7 | $11.09 | Dec 11, 2017 | M | 1,800 | D | — | Aug 27, 2018 | Common Stock | 1,800 | 150,655 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of common stock executed in multiple transactions at prices ranging from $56.11 to $56.84. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of common stock executed in multiple transactions at prices ranging from $55.10 to $56.07. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of common stock executed in multiple transactions at prices ranging from $54.08 to $55.06. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6Reflects sales of common stock executed in multiple transactions at prices ranging from $53.08 to $54.06. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F7Shares vested at a rate of 25% on 8/27/09 and monthly thereafter until all the shares were fully vested on 8/27/12.